LV12399B - IMPROVED SINGLE-DAY PUSH-BUTTON MINOCICLINE CARE SYSTEMS - Google Patents
IMPROVED SINGLE-DAY PUSH-BUTTON MINOCICLINE CARE SYSTEMS Download PDFInfo
- Publication number
- LV12399B LV12399B LVP-99-133A LV990133A LV12399B LV 12399 B LV12399 B LV 12399B LV 990133 A LV990133 A LV 990133A LV 12399 B LV12399 B LV 12399B
- Authority
- LV
- Latvia
- Prior art keywords
- parts
- granules
- weight
- release
- coated
- Prior art date
Links
- 229960004023 minocycline Drugs 0.000 title claims abstract description 44
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 title abstract 5
- 230000000541 pulsatile effect Effects 0.000 title 1
- 239000008187 granular material Substances 0.000 claims abstract description 141
- 239000000203 mixture Substances 0.000 claims abstract description 60
- 150000003839 salts Chemical class 0.000 claims abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 28
- 239000002253 acid Substances 0.000 claims abstract description 26
- 239000002775 capsule Substances 0.000 claims abstract description 25
- 231100000252 nontoxic Toxicity 0.000 claims abstract description 21
- 230000003000 nontoxic effect Effects 0.000 claims abstract description 21
- 239000000126 substance Substances 0.000 claims abstract description 8
- 229920002959 polymer blend Polymers 0.000 claims abstract 4
- 229920000642 polymer Polymers 0.000 claims description 72
- 238000000576 coating method Methods 0.000 claims description 59
- 239000011248 coating agent Substances 0.000 claims description 54
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 claims description 45
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 28
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 22
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 22
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 22
- 239000008188 pellet Substances 0.000 claims description 22
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 21
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 20
- 229930101283 tetracycline Natural products 0.000 claims description 18
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 16
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 16
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 230000000844 anti-bacterial effect Effects 0.000 claims description 14
- 239000004098 Tetracycline Substances 0.000 claims description 13
- 229960002180 tetracycline Drugs 0.000 claims description 13
- 235000019364 tetracycline Nutrition 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- 229920002301 cellulose acetate Polymers 0.000 claims description 12
- 239000007931 coated granule Substances 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000011734 sodium Substances 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- 150000003522 tetracyclines Chemical class 0.000 claims description 12
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 11
- 229940081735 acetylcellulose Drugs 0.000 claims description 10
- 238000013270 controlled release Methods 0.000 claims description 9
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 9
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims description 7
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 6
- 239000000049 pigment Substances 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 229920001249 ethyl cellulose Polymers 0.000 claims description 4
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 4
- 230000003179 granulation Effects 0.000 claims description 4
- 229920000609 methyl cellulose Polymers 0.000 claims description 4
- 239000001923 methylcellulose Substances 0.000 claims description 4
- 235000010981 methylcellulose Nutrition 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 239000011118 polyvinyl acetate Substances 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims 10
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 230000036765 blood level Effects 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 150000002772 monosaccharides Chemical class 0.000 claims 1
- 239000007901 soft capsule Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 18
- 239000008280 blood Substances 0.000 abstract description 18
- 230000001225 therapeutic effect Effects 0.000 abstract description 16
- 235000013305 food Nutrition 0.000 abstract description 6
- 238000007259 addition reaction Methods 0.000 abstract 1
- 238000011068 loading method Methods 0.000 description 45
- 239000002609 medium Substances 0.000 description 35
- 239000003814 drug Substances 0.000 description 32
- 229940079593 drug Drugs 0.000 description 19
- 239000002243 precursor Substances 0.000 description 19
- 210000002784 stomach Anatomy 0.000 description 18
- 229920002678 cellulose Polymers 0.000 description 15
- 235000010980 cellulose Nutrition 0.000 description 14
- 239000001913 cellulose Substances 0.000 description 14
- -1 minocycline compound Chemical class 0.000 description 14
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 11
- 229960002421 minocycline hydrochloride Drugs 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 7
- 210000001198 duodenum Anatomy 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229940110254 minocin Drugs 0.000 description 7
- 230000002035 prolonged effect Effects 0.000 description 7
- 108010010803 Gelatin Proteins 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 235000019365 chlortetracycline Nutrition 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000008273 gelatin Substances 0.000 description 6
- 229940014259 gelatin Drugs 0.000 description 6
- 229920000159 gelatin Polymers 0.000 description 6
- 235000019322 gelatine Nutrition 0.000 description 6
- 235000011852 gelatine desserts Nutrition 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000037406 food intake Effects 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 125000005498 phthalate group Chemical group 0.000 description 5
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 5
- 125000005591 trimellitate group Chemical group 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 239000008199 coating composition Substances 0.000 description 4
- 239000012738 dissolution medium Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000020828 fasting Nutrition 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007886 soft shell capsule Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229920001688 coating polymer Polymers 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000007887 hard shell capsule Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000001061 orange colorant Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 102100024133 Coiled-coil domain-containing protein 50 Human genes 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 101000910772 Homo sapiens Coiled-coil domain-containing protein 50 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 241000238367 Mya arenaria Species 0.000 description 2
- 206010037151 Psittacosis Diseases 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 201000000901 ornithosis Diseases 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010001986 Amoebic dysentery Diseases 0.000 description 1
- 241000606660 Bartonella Species 0.000 description 1
- 241000589968 Borrelia Species 0.000 description 1
- 241000180135 Borrelia recurrentis Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 241000459479 Capsula Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 235000005921 Cynara humilis Nutrition 0.000 description 1
- 240000002228 Cynara humilis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 244000182691 Echinochloa frumentacea Species 0.000 description 1
- 235000008247 Echinochloa frumentacea Nutrition 0.000 description 1
- 241000194032 Enterococcus faecalis Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000589602 Francisella tularensis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018693 Granuloma inguinale Diseases 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 206010035673 Pneumonia chlamydial Diseases 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 241000606723 Rickettsia akari Species 0.000 description 1
- 201000004282 Rickettsialpox Diseases 0.000 description 1
- SZKKRCSOSQAJDE-UHFFFAOYSA-N Schradan Chemical compound CN(C)P(=O)(N(C)C)OP(=O)(N(C)C)N(C)C SZKKRCSOSQAJDE-UHFFFAOYSA-N 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000613130 Tima Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000589904 Treponema pallidum subsp. pertenue Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000011203 antimicrobial therapy Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- XYZDGJMESCAYLB-PZBTWANTSA-N cfau Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C23B4B2B2B5B6B7B(B5C76)B4B32)=C1 XYZDGJMESCAYLB-PZBTWANTSA-N 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 108010082401 thymocyte interaction modulation factor Proteins 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 241000189072 typhus group Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 201000009482 yaws Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrotherapy Devices (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Magnetic Treatment Devices (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Laser Surgery Devices (AREA)
- Physical Deposition Of Substances That Are Components Of Semiconductor Devices (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Position Fixing By Use Of Radio Waves (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/844,109 US5262173A (en) | 1992-03-02 | 1992-03-02 | Pulsatile once-a-day delivery systems for minocycline |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV12399A LV12399A (lv) | 1999-12-20 |
| LV12399B true LV12399B (en) | 2000-06-20 |
Family
ID=25291839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-99-133A LV12399B (en) | 1992-03-02 | 1999-09-16 | IMPROVED SINGLE-DAY PUSH-BUTTON MINOCICLINE CARE SYSTEMS |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US5262173A (cs) |
| EP (1) | EP0558913B1 (cs) |
| JP (1) | JPH069407A (cs) |
| KR (1) | KR100270491B1 (cs) |
| CN (1) | CN1039194C (cs) |
| AT (1) | ATE181504T1 (cs) |
| AU (1) | AU656841B2 (cs) |
| CA (1) | CA2090561C (cs) |
| CZ (1) | CZ283684B6 (cs) |
| DE (1) | DE69325402T2 (cs) |
| DK (1) | DK0558913T3 (cs) |
| ES (1) | ES2134221T3 (cs) |
| FI (1) | FI110163B (cs) |
| GR (1) | GR3031028T3 (cs) |
| HU (1) | HU219580B (cs) |
| IL (1) | IL104865A (cs) |
| LV (1) | LV12399B (cs) |
| MX (1) | MX9300998A (cs) |
| NO (1) | NO307170B1 (cs) |
| NZ (1) | NZ245951A (cs) |
| PL (1) | PL171609B1 (cs) |
| SG (1) | SG47785A1 (cs) |
| TW (1) | TW299235B (cs) |
| ZA (1) | ZA931444B (cs) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4031881C2 (de) * | 1990-10-08 | 1994-02-24 | Sanol Arznei Schwarz Gmbh | Lösungsmittelfreie, oral zu verabreichende pharmazeutische Zubereitung mit verzögerter Wirkstoffreisetzung und Verfahren zu deren Herstellung |
| EP0804174A4 (en) * | 1993-07-21 | 1998-09-09 | Univ Kentucky Res Found | MULTI-CHAMBER HARD CAPSULES WITH CONTROLLED DELIVERY CHARACTERISTICS |
| US5538737A (en) * | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
| GB9518465D0 (en) * | 1995-09-09 | 1995-11-08 | Smithkline Beecham Seiyaku Kk | Pharmaceuticals |
| ZA974359B (en) * | 1996-05-23 | 1998-05-12 | Zeneca Ltd | Microencapsulated compositions. |
| US5932437A (en) * | 1998-04-13 | 1999-08-03 | Genesis Laboratories, Inc. | Control of lyme disease spirochete |
| WO2000019985A2 (en) * | 1998-10-01 | 2000-04-13 | Novartis Ag | New sustained release oral formulations |
| JP2000119181A (ja) * | 1998-10-06 | 2000-04-25 | Kureha Chem Ind Co Ltd | エスクレチン及びその誘導体の放出制御経口製剤 |
| US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
| US20090149479A1 (en) * | 1998-11-02 | 2009-06-11 | Elan Pharma International Limited | Dosing regimen |
| RU2236847C2 (ru) * | 1998-11-02 | 2004-09-27 | Илан Корпорейшн, Плк. | Композиции в виде множества частиц с модифицированным высвобождением |
| US6723342B1 (en) | 1999-02-08 | 2004-04-20 | Fmc Corporation | Edible coating composition |
| US6432448B1 (en) | 1999-02-08 | 2002-08-13 | Fmc Corporation | Edible coating composition |
| US20050137181A1 (en) * | 1999-03-17 | 2005-06-23 | Bonner Ernest L. | Method for treatment of reactive arthritis or bursitis |
| US7691831B2 (en) * | 1999-03-17 | 2010-04-06 | Ernest L. Bonner, Jr. | Pharmaceutical combination and method for treatment of reactive arthritis or bursitis |
| US6765000B2 (en) * | 1999-03-17 | 2004-07-20 | Bonner Jr Ernest L | Treatment for reactive arthritis or bursitis |
| US7884090B2 (en) * | 1999-03-17 | 2011-02-08 | Ernest L. Bonner, Jr. | Compositions and methods for the treatment of arthritis |
| EP1165054A4 (en) | 1999-04-06 | 2005-02-09 | Pharmaquest Ltd | PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT DELIVERY OF METHYLPHENIDATE |
| US20030170181A1 (en) * | 1999-04-06 | 2003-09-11 | Midha Kamal K. | Method for preventing abuse of methylphenidate |
| EP1231901A4 (en) * | 1999-10-29 | 2005-03-23 | Fmc Corp | EDIBLE COATING COMPOSITION |
| CA2389235C (en) | 1999-10-29 | 2007-07-17 | Euro-Celtique, S.A. | Controlled release hydrocodone formulations |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| US6500462B1 (en) | 1999-10-29 | 2002-12-31 | Fmc Corporation | Edible MCC/PGA coating composition |
| KR100968128B1 (ko) | 2000-10-30 | 2010-07-06 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
| BR0115585A (pt) | 2000-11-28 | 2005-12-13 | Fmc Corp | Composições de revestimento de pronta liberação, endurecìvel, comestìvel, seca e, úmida, forma de dosagem sólida, e, método para revestir uma forma de dosagem sólida farmacêutica ou veterinária, confeito, semente, ração animal, fertilizante, comprimido de pesticida ou alimento |
| US6932861B2 (en) | 2000-11-28 | 2005-08-23 | Fmc Corporation | Edible PGA coating composition |
| WO2002083106A1 (en) * | 2001-04-05 | 2002-10-24 | Collagenex Pharmaceuticals, Inc. | Controlled delivery of tetracycline compounds and tetracycline derivatives |
| CA2449731A1 (en) * | 2001-06-07 | 2002-12-19 | Tanabe Seiyaku Co., Ltd. | Functional grain-containing preparations quickly disintegrated in the oral cavity |
| US6958161B2 (en) | 2002-04-12 | 2005-10-25 | F H Faulding & Co Limited | Modified release coated drug preparation |
| AU2003250218B2 (en) | 2002-12-20 | 2006-10-26 | F. Hoffmann-La Roche Ag | High dose Ibandronate formulation |
| ES2534827T3 (es) | 2003-04-07 | 2015-04-29 | Supernus Pharmaceuticals, Inc. | Formulaciones de tetraciclinas en dosis única diaria |
| GB2414668B (en) * | 2004-06-03 | 2009-07-29 | Dexcel Ltd | Tetracycline modified release delivery system |
| JP5563735B2 (ja) | 2004-06-16 | 2014-07-30 | タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド | Ｐｐｉ多回剤形 |
| US20060121112A1 (en) * | 2004-12-08 | 2006-06-08 | Elan Corporation, Plc | Topiramate pharmaceutical composition |
| JP2008535922A (ja) * | 2005-04-12 | 2008-09-04 | エラン・ファルマ・インターナショナル・リミテッド | 細菌感染を治療するためのセファロスポリンを含む放出制御組成物 |
| US7541347B2 (en) * | 2007-04-02 | 2009-06-02 | Medicis Pharmaceutical Coropration | Minocycline oral dosage forms for the treatment of acne |
| US8252776B2 (en) | 2007-04-02 | 2012-08-28 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US7544373B2 (en) * | 2007-04-02 | 2009-06-09 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US20080242642A1 (en) | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US9192615B2 (en) | 2008-08-06 | 2015-11-24 | Medicis Pharmaceutical Corporation | Method for the treatment of acne and certain dosage forms thereof |
| US20080241235A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline oral dosage forms for the treatment of acne |
| US8722650B1 (en) | 2005-06-24 | 2014-05-13 | Medicis Pharmaceutical Corporation | Extended-release minocycline dosage forms |
| US7919483B2 (en) * | 2005-06-24 | 2011-04-05 | Medicis Pharmaceutical Corporation | Method for the treatment of acne |
| US20080318910A1 (en) * | 2005-10-04 | 2008-12-25 | Mistral Pharma, Inc. | Controlled-Release Oral Dosage Form |
| US20070166273A1 (en) * | 2006-01-19 | 2007-07-19 | Krivulka Joseph J | Skin treatment educational kit |
| PT103661B (pt) * | 2007-02-23 | 2010-09-07 | Hovione Farmaciencia S A | Processo de preparação de minociclina base cristalina |
| CA2684985A1 (en) * | 2007-03-16 | 2008-09-25 | Elan Pharma International Limited | Combination of a narcotic and a non-narcotic analgesic |
| US20080241197A1 (en) * | 2007-04-02 | 2008-10-02 | Medicis Pharmaceutical Corporation | Minocycline dosage forms for the treatment of acne |
| RU2010119041A (ru) | 2007-10-12 | 2011-11-20 | Такеда Фармасьютикалз Норт Америка, Инк. (Us) | Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи |
| EP2699236B1 (en) | 2011-04-22 | 2018-06-20 | Napo Pharmaceuticals Inc | Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga) |
| WO2012150246A1 (de) | 2011-05-05 | 2012-11-08 | Hennig Arzneimittel Gmbh & Co. Kg | Arzneiform zur gezielten freigabe von wirkstoffen |
| DE102011075354A1 (de) * | 2011-05-05 | 2012-11-08 | Hennig Arzneimittel Gmbh & Co. Kg | Arzneiform zur gezielten Freigabe von Wirkstoffen |
| US9561241B1 (en) | 2011-06-28 | 2017-02-07 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for minocycline |
| US11103517B2 (en) | 2015-04-07 | 2021-08-31 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions for minocycline |
| CN108414466A (zh) * | 2018-03-09 | 2018-08-17 | 浙江美华鼎昌医药科技有限公司 | 一种盐酸米诺环素缓释片体外溶出测定方法 |
| MX2020011599A (es) * | 2018-04-30 | 2021-01-15 | Melinta Therapeutics Inc | Métodos de tratamiento de infecciones bacterianas con minociclina. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL122039C (cs) * | 1960-10-20 | |||
| US3865935A (en) * | 1972-08-10 | 1975-02-11 | Abbott Lab | Tableting of erythromycin base |
| US4250166A (en) * | 1977-05-27 | 1981-02-10 | Shionogi & Co., Ltd. | Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin |
| GB1561204A (en) * | 1977-06-01 | 1980-02-13 | Ici Ltd | Sustained release pharmaceutical composition |
| US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| FR2447192A1 (fr) * | 1979-01-25 | 1980-08-22 | Adria Lab Inc | Forme galenique a liberation prolongee d'indoprofene |
| US4353887A (en) * | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
| DK150008C (da) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
| JPS61210025A (ja) * | 1985-03-14 | 1986-09-18 | Teisan Seiyaku Kk | 安定化された抗生物質複合顆粒製剤 |
| GB8521494D0 (en) * | 1985-08-29 | 1985-10-02 | Zyma Sa | Controlled release tablet |
| US4808413A (en) * | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
| US4837030A (en) * | 1987-10-06 | 1989-06-06 | American Cyanamid Company | Novel controlled release formulations of tetracycline compounds |
| EP0327295A3 (en) * | 1988-02-01 | 1989-09-06 | F.H. FAULDING & CO. LTD. | Tetracycline dosage form |
| US5133974A (en) * | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| ES2064564T3 (es) * | 1989-09-21 | 1995-02-01 | American Cyanamid Co | Sistema de liberacion pulsatil de dosis unitaria diaria de minociclina. |
| EP0418596A3 (en) * | 1989-09-21 | 1991-10-23 | American Cyanamid Company | Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form |
| IT1241417B (it) * | 1990-03-06 | 1994-01-14 | Vectorpharma Int | Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione |
| US5286497A (en) * | 1991-05-20 | 1994-02-15 | Carderm Capital L.P. | Diltiazem formulation |
-
1992
- 1992-03-02 US US07/844,109 patent/US5262173A/en not_active Expired - Lifetime
-
1993
- 1993-01-25 DK DK93101096T patent/DK0558913T3/da active
- 1993-01-25 ES ES93101096T patent/ES2134221T3/es not_active Expired - Lifetime
- 1993-01-25 SG SG1996004364A patent/SG47785A1/en unknown
- 1993-01-25 EP EP93101096A patent/EP0558913B1/en not_active Expired - Lifetime
- 1993-01-25 AT AT93101096T patent/ATE181504T1/de not_active IP Right Cessation
- 1993-01-25 DE DE69325402T patent/DE69325402T2/de not_active Expired - Lifetime
- 1993-02-22 NZ NZ245951A patent/NZ245951A/en not_active IP Right Cessation
- 1993-02-24 MX MX9300998A patent/MX9300998A/es unknown
- 1993-02-25 CN CN93101947A patent/CN1039194C/zh not_active Expired - Lifetime
- 1993-02-25 IL IL10486593A patent/IL104865A/xx not_active IP Right Cessation
- 1993-02-26 AU AU33842/93A patent/AU656841B2/en not_active Expired
- 1993-02-26 CA CA002090561A patent/CA2090561C/en not_active Expired - Lifetime
- 1993-02-27 KR KR1019930002984A patent/KR100270491B1/ko not_active Expired - Lifetime
- 1993-03-01 CZ CZ93300A patent/CZ283684B6/cs not_active IP Right Cessation
- 1993-03-01 ZA ZA931444A patent/ZA931444B/xx unknown
- 1993-03-01 PL PL93297903A patent/PL171609B1/pl unknown
- 1993-03-01 HU HU9300570A patent/HU219580B/hu not_active IP Right Cessation
- 1993-03-01 FI FI930906A patent/FI110163B/fi not_active IP Right Cessation
- 1993-03-01 JP JP5062500A patent/JPH069407A/ja active Pending
- 1993-03-01 NO NO930743A patent/NO307170B1/no not_active IP Right Cessation
- 1993-04-02 TW TW082102503A patent/TW299235B/zh active
- 1993-06-23 US US08/081,632 patent/US5348748A/en not_active Expired - Lifetime
-
1999
- 1999-08-18 GR GR990402106T patent/GR3031028T3/el unknown
- 1999-09-16 LV LVP-99-133A patent/LV12399B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LV12399B (en) | IMPROVED SINGLE-DAY PUSH-BUTTON MINOCICLINE CARE SYSTEMS | |
| CA2025703C (en) | Pulsatile once-a-day delivery systems for minocycline | |
| EP0310814B1 (en) | Novel controlled release formulations of tetracycline compounds | |
| HK1000315B (en) | Pulsatile once-a-day delivery system for minocycline | |
| HK1000313B (en) | Novel controlled release formulations of tetracycline compounds | |
| US5776489A (en) | Controlled release carbonic anhydrase inhibitor containing pharmaceutical compositions from spherical granules in capsule oral dosage unit form | |
| HK1009930B (en) | Improved pulsatile once-a-day delivery systems for minocycline | |
| NO177554B (no) | Fremgangsmåte for fremstilling av en multiovertrukket sammensetning som utgjör et farmasöytisk doseringssystem |